CA3208713A1 - Kv1.3 blockers - Google Patents

Kv1.3 blockers Download PDF

Info

Publication number
CA3208713A1
CA3208713A1 CA3208713A CA3208713A CA3208713A1 CA 3208713 A1 CA3208713 A1 CA 3208713A1 CA 3208713 A CA3208713 A CA 3208713A CA 3208713 A CA3208713 A CA 3208713A CA 3208713 A1 CA3208713 A1 CA 3208713A1
Authority
CA
Canada
Prior art keywords
nle
amino acid
seq
ion channel
channel blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3208713A
Other languages
English (en)
French (fr)
Inventor
Henrik Fischer MUNCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of CA3208713A1 publication Critical patent/CA3208713A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3208713A 2021-03-23 2022-03-22 Kv1.3 blockers Pending CA3208713A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21164384 2021-03-23
EP21164384.6 2021-03-23
EP21213431 2021-12-09
EP21213431.6 2021-12-09
PCT/EP2022/057533 WO2022200374A1 (en) 2021-03-23 2022-03-22 Kv1.3 blockers

Publications (1)

Publication Number Publication Date
CA3208713A1 true CA3208713A1 (en) 2022-09-29

Family

ID=80952156

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3208713A Pending CA3208713A1 (en) 2021-03-23 2022-03-22 Kv1.3 blockers

Country Status (12)

Country Link
US (1) US20240182531A1 (enExample)
EP (1) EP4314024A1 (enExample)
JP (1) JP2024511449A (enExample)
KR (1) KR20230159403A (enExample)
AU (1) AU2022245193A1 (enExample)
BR (1) BR112023019022A2 (enExample)
CA (1) CA3208713A1 (enExample)
CL (1) CL2023002590A1 (enExample)
IL (1) IL305219A (enExample)
MX (1) MX2023010930A (enExample)
TW (1) TW202304957A (enExample)
WO (1) WO2022200374A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604984A1 (en) * 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
JP2016527250A (ja) 2013-07-22 2016-09-08 キネタ ワン リミテッド ライアビリティ カンパニーＫｉｎｅｔａ Ｏｎｅ，Ｌｌｃ 毒素系治療用ペプチド及びその医薬組成物の眼科的使用
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
EP4031162A1 (en) * 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers

Also Published As

Publication number Publication date
US20240182531A1 (en) 2024-06-06
EP4314024A1 (en) 2024-02-07
JP2024511449A (ja) 2024-03-13
CL2023002590A1 (es) 2024-03-15
AU2022245193A1 (en) 2023-09-07
IL305219A (en) 2023-10-01
BR112023019022A2 (pt) 2023-10-17
WO2022200374A1 (en) 2022-09-29
KR20230159403A (ko) 2023-11-21
TW202304957A (zh) 2023-02-01
MX2023010930A (es) 2023-09-28

Similar Documents

Publication Publication Date Title
US11780893B2 (en) Kv1.3 blockers
US10905745B2 (en) Acylated GLP-1/GLP-2 dual agonists
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
NZ576260A (en) GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
EP3551652A1 (en) Glp-1/glp-2 dual agonists
EP2320923B1 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
WO2018103868A1 (en) Acylated glp-1/glp-2 dual agonists
AU2003302610B2 (en) Novel chi-conotoxin peptides (-II)
IL305219A (en) Line suppressors 1.3 which have been changed
RU2825633C1 (ru) БЛОКАТОРЫ Kv1.3
EP4604984A1 (en) Inhibitors
CN117255798A (zh) Kv1.3阻断剂
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
HK40007709B (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists
HK1164340A (en) Chi-conotoxin peptides (ii)

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250319

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250319

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224